Radiotherapy Combined with Immunotherapy and Chemotherapy Improves Prognosis and Demonstrates Synergistic Effects in Extensive-stage Small Cell Lung Cancer
Background and objective Extensive-stage small cell lung cancer (ES-SCLC) is a malignant tumor with remarkable proliferative and invasive ability, which has very poor clinical prognosis due to lack of effective treatments. This study aims to evaluate the efficacy and synergistic effects of radiother...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2024-11-01
|
| Series: | Chinese Journal of Lung Cancer |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2024.102.41 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841544080248537088 |
|---|---|
| author | Huaijun JI Meiling SUN Jingyi LI Ge YU Yongbing CHEN |
| author_facet | Huaijun JI Meiling SUN Jingyi LI Ge YU Yongbing CHEN |
| author_sort | Huaijun JI |
| collection | DOAJ |
| description | Background and objective Extensive-stage small cell lung cancer (ES-SCLC) is a malignant tumor with remarkable proliferative and invasive ability, which has very poor clinical prognosis due to lack of effective treatments. This study aims to evaluate the efficacy and synergistic effects of radiotherapy (RT) combined with immunotherapy (IT) and chemotherapy (CT) in patients with ES-SCLC. Methods A retrospective analysis was performed on 145 ES-SCLC patients treated with first-line CT. Kaplan-Meier analysis and Log-rank tests were used to evaluate survival outcomes, while propensity score matching (PSM) was applied to reduce confounding factors. Results The median overall survival (mOS) and median progression-free survival (mPFS) for the entire cohort were 15.7 and 6.9 mon, respectively. The IT+CT group had a significantly longer mOS compared to the CT group (17.2 vs 13.5 mon, P=0.047). Similarly, the RT+CT group demonstrated superior mOS (18.5 vs 12.3 mon, P<0.001) and mPFS (7.1 vs 6.2 mon, P=0.006) compared to the CT group. Multivariate analysis identified RT, IT, and Eastern Cooperative Oncology Group performance status (ECOG PS) as independent prognostic factors for mOS (P<0.05), while gender and ECOG PS were independent predictors for mPFS (P<0.05). Following PSM, the RT+CT group continued to exhibit significant advantages in mOS (18.0 vs 12.1 mon, P<0.001) and mPFS (7.1 vs 5.5 mon, P=0.037) compared to the CT group. Notably, the RT+IT+CT group achieved a markedly longer mOS than the IT+CT group (28.5 vs 15.8 mon, P=0.017). Grade 3-4 adverse events occurred in 27.6% of patients, with no grade 5 adverse events reported. Conclusion The combination of RT, IT, and CT significantly enhances the prognosis of ES-SCLC patients. RT plays a key role in their synergistic effects and demonstrates good safety, warranting further research and clinical application. |
| format | Article |
| id | doaj-art-695c67a990e5493d9d3b87f3d226fe13 |
| institution | Kabale University |
| issn | 1009-3419 1999-6187 |
| language | zho |
| publishDate | 2024-11-01 |
| publisher | Chinese Anti-Cancer Association; Chinese Antituberculosis Association |
| record_format | Article |
| series | Chinese Journal of Lung Cancer |
| spelling | doaj-art-695c67a990e5493d9d3b87f3d226fe132025-01-13T02:46:02ZzhoChinese Anti-Cancer Association; Chinese Antituberculosis AssociationChinese Journal of Lung Cancer1009-34191999-61872024-11-01271183183910.3779/j.issn.1009-3419.2024.102.41Radiotherapy Combined with Immunotherapy and Chemotherapy Improves Prognosis and Demonstrates Synergistic Effects in Extensive-stage Small Cell Lung CancerHuaijun JI0Meiling SUN1Jingyi LI2Ge YU3Yongbing CHEN4Department of Thoracic Surgery, The Second Affiliated Hospital of Soochow University, Suzhou 215000, ChinaDepartment of Respiratory and Critical Care Medicine,
Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai 264200, ChinaDepartment of Radiation Oncology,
Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai 264200, ChinaDepartment of Thoracic Surgery,
Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai 264200, ChinaDepartment of Thoracic Surgery, The Second Affiliated Hospital of Soochow University, Suzhou 215000, ChinaBackground and objective Extensive-stage small cell lung cancer (ES-SCLC) is a malignant tumor with remarkable proliferative and invasive ability, which has very poor clinical prognosis due to lack of effective treatments. This study aims to evaluate the efficacy and synergistic effects of radiotherapy (RT) combined with immunotherapy (IT) and chemotherapy (CT) in patients with ES-SCLC. Methods A retrospective analysis was performed on 145 ES-SCLC patients treated with first-line CT. Kaplan-Meier analysis and Log-rank tests were used to evaluate survival outcomes, while propensity score matching (PSM) was applied to reduce confounding factors. Results The median overall survival (mOS) and median progression-free survival (mPFS) for the entire cohort were 15.7 and 6.9 mon, respectively. The IT+CT group had a significantly longer mOS compared to the CT group (17.2 vs 13.5 mon, P=0.047). Similarly, the RT+CT group demonstrated superior mOS (18.5 vs 12.3 mon, P<0.001) and mPFS (7.1 vs 6.2 mon, P=0.006) compared to the CT group. Multivariate analysis identified RT, IT, and Eastern Cooperative Oncology Group performance status (ECOG PS) as independent prognostic factors for mOS (P<0.05), while gender and ECOG PS were independent predictors for mPFS (P<0.05). Following PSM, the RT+CT group continued to exhibit significant advantages in mOS (18.0 vs 12.1 mon, P<0.001) and mPFS (7.1 vs 5.5 mon, P=0.037) compared to the CT group. Notably, the RT+IT+CT group achieved a markedly longer mOS than the IT+CT group (28.5 vs 15.8 mon, P=0.017). Grade 3-4 adverse events occurred in 27.6% of patients, with no grade 5 adverse events reported. Conclusion The combination of RT, IT, and CT significantly enhances the prognosis of ES-SCLC patients. RT plays a key role in their synergistic effects and demonstrates good safety, warranting further research and clinical application.http://dx.doi.org/10.3779/j.issn.1009-3419.2024.102.41lung neoplasmsimmunotherapyradiotherapysynergistic effect |
| spellingShingle | Huaijun JI Meiling SUN Jingyi LI Ge YU Yongbing CHEN Radiotherapy Combined with Immunotherapy and Chemotherapy Improves Prognosis and Demonstrates Synergistic Effects in Extensive-stage Small Cell Lung Cancer Chinese Journal of Lung Cancer lung neoplasms immunotherapy radiotherapy synergistic effect |
| title | Radiotherapy Combined with Immunotherapy and Chemotherapy Improves Prognosis and Demonstrates Synergistic Effects in Extensive-stage Small Cell Lung Cancer |
| title_full | Radiotherapy Combined with Immunotherapy and Chemotherapy Improves Prognosis and Demonstrates Synergistic Effects in Extensive-stage Small Cell Lung Cancer |
| title_fullStr | Radiotherapy Combined with Immunotherapy and Chemotherapy Improves Prognosis and Demonstrates Synergistic Effects in Extensive-stage Small Cell Lung Cancer |
| title_full_unstemmed | Radiotherapy Combined with Immunotherapy and Chemotherapy Improves Prognosis and Demonstrates Synergistic Effects in Extensive-stage Small Cell Lung Cancer |
| title_short | Radiotherapy Combined with Immunotherapy and Chemotherapy Improves Prognosis and Demonstrates Synergistic Effects in Extensive-stage Small Cell Lung Cancer |
| title_sort | radiotherapy combined with immunotherapy and chemotherapy improves prognosis and demonstrates synergistic effects in extensive stage small cell lung cancer |
| topic | lung neoplasms immunotherapy radiotherapy synergistic effect |
| url | http://dx.doi.org/10.3779/j.issn.1009-3419.2024.102.41 |
| work_keys_str_mv | AT huaijunji radiotherapycombinedwithimmunotherapyandchemotherapyimprovesprognosisanddemonstratessynergisticeffectsinextensivestagesmallcelllungcancer AT meilingsun radiotherapycombinedwithimmunotherapyandchemotherapyimprovesprognosisanddemonstratessynergisticeffectsinextensivestagesmallcelllungcancer AT jingyili radiotherapycombinedwithimmunotherapyandchemotherapyimprovesprognosisanddemonstratessynergisticeffectsinextensivestagesmallcelllungcancer AT geyu radiotherapycombinedwithimmunotherapyandchemotherapyimprovesprognosisanddemonstratessynergisticeffectsinextensivestagesmallcelllungcancer AT yongbingchen radiotherapycombinedwithimmunotherapyandchemotherapyimprovesprognosisanddemonstratessynergisticeffectsinextensivestagesmallcelllungcancer |